{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:41:32Z","timestamp":1792190492500,"version":"4.4.0"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor that demonstrated superior efficacy versus placebo and apremilast in a global phase 3 trial (POETYK PSO\u20101; NCT03624127) in patients with moderate to severe plaque psoriasis (\n                    <jats:italic>N<\/jats:italic>\n                    \u00a0=\u2009666). This report describes efficacy and safety in Japanese patients from this study (\n                    <jats:italic>N<\/jats:italic>\n                    \u00a0=\u200966) who were randomly assigned to treatment with deucravacitinib 6\u00a0mg once daily (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u200932), placebo (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u200917), or apremilast 30\u2009mg twice daily (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u200917). Patients randomized to placebo crossed over to deucravacitinib at Week 16. Patients randomized to apremilast who did not achieve \u226550% reduction from baseline in Psoriasis Area and Severity Index (PASI 50) score at Week 24 switched to deucravacitinib. The proportion of Japanese patients achieving \u226575% reduction from baseline in PASI (PASI 75) score\u00a0was numerically higher with deucravacitinib versus placebo and apremilast at Week 16 (78.1% vs. 11.8% and 23.5%, respectively) and versus apremilast at Week 24 (78.1% vs. 29.4%). A numerically higher proportion of patients achieved a static Physician's Global Assessment score of 0 or 1 (clear or almost clear) with at least a two\u2010point improvement from baseline (sPGA 0\/1) with deucravacitinib versus placebo or apremilast at Week 16 (75.0% vs. 11.8% and 35.3%) and versus apremilast at Week 24 (75.0% vs. 29.4%). Findings for other clinical and patient\u2010reported outcomes also favored deucravacitinib. Response rates were maintained through 52\u2009weeks in the deucravacitinib group. Incidence rates for adverse events per 100 person\u2010years (PY) in the Japanese patients were comparable across treatment groups through Week 52 (deucravacitinib, 336.8\/100 PY; placebo, 321.0\/100 PY; apremilast, 358.6\/100 PY). The most frequently reported adverse event with deucravacitinib was nasopharyngitis. The efficacy and safety of deucravacitinib in Japanese patients was consistent with those in the global population in POETYK PSO\u20101.\n                  <\/jats:p>","DOI":"10.1111\/1346-8138.16740","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:25:11Z","timestamp":1678235111000},"page":"588-595","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy and safety of the selective\n                    <scp>TYK2<\/scp>\n                    inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double\u2010blind, placebo\u2010controlled, global phase 3 trial"],"prefix":"10.1111","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-4349","authenticated-orcid":false,"given":"Shinichi","family":"Imafuku","sequence":"first","affiliation":[{"name":"Fukuoka University  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[{"name":"Teikyo University  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Hippeli","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashis","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-3754","authenticated-orcid":false,"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Nagoya City University Graduate School of Medical Sciences  Nagoya Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamitaro","family":"Ohtsuki","sequence":"additional","affiliation":[{"name":"Jichi Medical University  Shimotsuke Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.82"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16092"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15803"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0205-2"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15196"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13466"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444"},{"key":"e_1_2_8_11_1","unstructured":"SOTYKTUTM (deucravacitinib) [package insert]. Princeton NJ: Bristol Myers Squibb; September2022. Available at:https:\/\/packageinserts.bms.com\/pi\/pi_sotyktu.pdf. Accessed February 7 2023."},{"key":"e_1_2_8_12_1","unstructured":"SOTYKTU Japan [package insert]. Tokyo Japan: Bristol Myers Squibb K.K.; September2022."},{"key":"e_1_2_8_13_1","unstructured":"An investigational study to evaluate experimental medication BMS\u2010986165 compared to placebo and a currently available treatment in participants with moderate\u2010to\u2010severe plaque psoriasis (POETYK\u2010PSO\u20102) [NCT03611751].2020. Available at:https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03611751?term=NCT03611751&draw=2&rank=1. Accessed November 15 2021."},{"key":"e_1_2_8_14_1","unstructured":"An investigational study to evaluate experimental medication BMS\u2010986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis (POETYK PSO\u20101) [NCT03624127].2020. Available at:https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03624127?term=NCT03624127&draw=2&rank=1. Accessed December 2 2022."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_2_8_17_1","unstructured":"Bristol Myers Squibb presents positive data from two pivotal phase 3 psoriasis studies demonstrating superiority of deucravacitinib compared to placebo and Otezla\u00ae (apremilast) [press release].2021. Available at:https:\/\/news.bms.com\/news\/details\/2021\/Bristol\u2010Myers\u2010Squibb\u2010Presents\u2010Positive\u2010Data\u2010from\u2010Two\u2010Pivotal\u2010Phase\u20103\u2010Psoriasis\u2010Studies\u2010Demonstrating\u2010Superiority\u2010of\u2010Deucravacitinib\u2010Compared\u2010to\u2010Placebo\u2010and\u2010Otezla\u2010apremilast\/default.aspx. Accessed November 15 2021."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdds.2015.07.004"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1114567"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13829"},{"key":"e_1_2_8_21_1","unstructured":"An investigative study to evaluate experimental medication BMS\u2010986165 in Japanese participants with moderate\u2010to\u2010severe psoriasis [NCT03924427].2022. Available at:https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03924427?term=NCT03924427&draw=2&rank=1. Accessed December 2 2022."}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16740","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.16740","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T08:30:46Z","timestamp":1692693046000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.16740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/1346-8138.16740"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.16740","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"assertion":[{"value":"2022-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}